Balanced news tone
News Sentiment
INKT sentiment intelligence
Mink Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
53
Balanced news tone
60 relevant articles
News tone and price action are not far from neutral.
81/100 classification confidence.
directly relevant articles
high-authority source matches
-3.5% over one week, -12.2% over four weeks, trend inactive, and near fair-value range.
Here's Why You Should Add INKT Stock to Your Portfolio Now
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
81/100 classification
One-week reaction
-3.5%
Price reacting lower
Trend fit
Trend inactive
-12.2% over four weeks
Fair value
-1.2%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
11
Neutral
46
Negative
3
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Industry context
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jul 2026 18:49
- Source
- Market source
TradingView
Direct company coverage
Here's Why You Should Add INKT Stock to Your Portfolio Now
MiNK Therapeutics (INKT) is a biotechnology company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for various life-threatening diseases, including oncology and respiratory conditions. The company's lead candidate, agenT-797, is showing promisin
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 16 Jul 2026 16:41
- Source
- TradingView
Zacks Investment Research
Direct company coverage
What date does MiNK Therapeutics, Inc.'s (INKT) report Earnings - Earnings Calendar & Announcement
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jul 2026 07:00
- Source
- Zacks Investment Research
Stock Traders Daily
Direct company coverage
Why (INKT) Price Action Is Critical for Tactical Trading
This article analyzes Mink Therapeutics Inc. (NASDAQ: INKT) with a focus on its price action for tactical trading, identifying weak sentiment across all horizons and supporting a short bias. It details an exceptional risk-reward setup targeting a 54.4% gain versus 0.3% risk, and
- Tone
- Negative 30/100
- Event
- Market update
- Published
- 13 Jul 2026 23:40
- Source
- Stock Traders Daily
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 07:00
- Source
- Market source
Quartr
Direct company coverage
Mink Therapeutics (INKT) Proxy filing Summary
Mink Therapeutics (INKT) has released a proxy filing summary ahead of its Annual Meeting on June 17, 2026. The meeting will address the election of three Class II directors and the ratification of KPMG LLP as the independent registered public accounting firm. Stockholders as of A
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 23:09
- Source
- Quartr
Quartr
Direct company coverage
Mink Therapeutics (INKT) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary
Mink Therapeutics presented a summary of their pipeline and development status at the H.C. Wainwright 26th Annual Global Investment Conference 2024. The company focuses on off-the-shelf invariant natural killer T (iNKT) cell therapies, with their lead program agenT-797 in Phase I
- Tone
- Positive 72/100
- Event
- Market update
- Published
- 10 Jul 2026 19:09
- Source
- Quartr
Quartr
Direct company coverage
Mink Therapeutics (INKT) Q1 2025 earnings summary
Mink Therapeutics (INKT) announced Q1 2025 financial results, reporting a net loss of $2.8 million and a cash balance of $3.2 million. The company achieved significant clinical milestones in cancer therapy and secured probable NIAID funding for its GVHD program, expecting to pres
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 09 Jul 2026 04:40
- Source
- Quartr
TradingView
Direct company coverage
Cost of goods sold of MiNK Therapeutics, Inc. – DUS:6Q40
This article focuses on the "Cost of goods sold" for MiNK Therapeutics, Inc., specifically for its listing on the Dusseldorf Stock Exchange under the ticker 6Q40. The content is presented as a financial data point within the broader context of the company's financial overview on
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jul 2026 05:39
- Source
- TradingView
Stock Traders Daily
Direct company coverage
Understanding Momentum Shifts in (INKT)
This article provides an in-depth analysis of Mink Therapeutics Inc. (NASDAQ: INKT) utilizing AI models to identify momentum shifts and suggest trading strategies. It highlights a near-term weak sentiment that may lead to a resumption of long-term weakness after a neutral shift,
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 22:32
- Source
- Stock Traders Daily
www.marketscreener.com
Direct company coverage
MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell Microcap Value Benchmark Index
MiNK Therapeutics, Inc. (NasdaqCM:INKT) has been added to the Russell Microcap Value Benchmark Index, as reported on June 29, 2026. This inclusion signifies the company's recognition within the microcap investment community. The clinical-stage biopharmaceutical company focuses on
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 16:32
- Source
- www.marketscreener.com
marketscreener.com
Direct company coverage
MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell 3000E Value Benchmark
MiNK Therapeutics, Inc. (NasdaqCM: INKT) has been added to the Russell 3000E Value Benchmark Index. This inclusion highlights the company's growing presence in the financial markets and follows several other recent inclusions in various Russell Microcap and 3000E indices. MiNK Th
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 29 Jun 2026 15:40
- Source
- marketscreener.com
marketscreener.com
Direct company coverage
MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell Microcap Growth Benchmark Index
MiNK Therapeutics, Inc. (NasdaqCM: INKT) has been added to the Russell Microcap Growth Benchmark Index. This inclusion means the company's stock will now be tracked by this widely recognized index, potentially increasing its visibility and attractiveness to growth-focused investo
- Tone
- Positive 75/100
- Event
- Market update
- Published
- 29 Jun 2026 12:28
- Source
- marketscreener.com
marketscreener.com
Direct company coverage
MiNK Therapeutics, Inc.(NasdaqCM: INKT) added to Russell Microcap Index
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 07:00
- Source
- marketscreener.com
marketscreener.com
Direct company coverage
MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell Microcap Index
MiNK Therapeutics, Inc. (NasdaqCM: INKT), a clinical-stage biopharmaceutical company focused on allogeneic invariant natural killer T (iNKT) cell therapies, has been added to the Russell Microcap Index. This inclusion follows several recent developments for the company, including
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 29 Jun 2026 05:41
- Source
- marketscreener.com
www.marketscreener.com
Direct company coverage
MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell 3000E Growth Benchmark
MiNK Therapeutics, Inc. (NasdaqCM: INKT) has been added to the Russell 3000E Growth Benchmark. This inclusion follows previous additions to the Russell Microcap Value and Microcap Growth Benchmark Indexes. MiNK Therapeutics is a clinical-stage biopharmaceutical company focused on
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 29 Jun 2026 04:46
- Source
- www.marketscreener.com
TradingView
Direct company coverage
INKT Forecast — Price Target — Prediction for 2027
This article provides a forecast for MiNK Therapeutics, Inc. (INKT) stock, including analyst price targets and a prediction for 2027. It details the current stock price, historical performance, market capitalization, and upcoming earnings report. The piece also addresses frequent
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 28 Jun 2026 07:41
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to EBITDA forward of MiNK Therapeutics, Inc. – NASDAQ:INKT
The article provides financial data for MiNK Therapeutics, Inc. (NASDAQ: INKT), focusing on its enterprise value to EBITDA forward. It indicates the stock is listed on the Nasdaq Stock Market and that the market was closed at the time of publication, with no trades observed.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 16:10
- Source
- TradingView
TradingView
Direct company coverage
MiNK Therapeutics, Inc. Actuals & Estimates (NASDAQ:INKT)
This article provides an overview of MiNK Therapeutics, Inc. (NASDAQ:INKT) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the company's market capitalization, upcoming earnings date, and past earnings and revenue f
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 09:10
- Source
- TradingView
TradingView
Direct company coverage
Price to earnings forward of MiNK Therapeutics, Inc. – NASDAQ:INKT
The article focuses on the "Price to earnings forward" financial metric for MiNK Therapeutics, Inc. (NASDAQ: INKT). It provides a snapshot of this financial data on the TradingView platform, noting that the market was closed with no trades at the time of viewing.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 09:09
- Source
- TradingView
Simply Wall Street
Direct company coverage
MiNK Therapeutics (Nasdaq:INKT) - Stock Analysis
MiNK Therapeutics (Nasdaq:INKT) is a clinical-stage biopharmaceutical company focused on allogeneic, off-the-shelf iNKT cell therapies for cancer and immune-mediated diseases. The company is currently trading significantly below its estimated fair value and faces risks including
- Tone
- Positive 65/100
- Event
- Market update
- Published
- 24 Jun 2026 23:10
- Source
- Simply Wall Street
Investing.com Nigeria
Direct company coverage
Form 8K Mink Therapeutics Inc For: 23 June By Investing.com
This article reports that Mink Therapeutics Inc. filed a Form 8K on June 23, 2026. This filing is a standard requirement for significant events that shareholders should be aware of. The article also provides current market data for various indices, commodities, bonds, and shares,
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Jun 2026 10:41
- Source
- Investing.com Nigeria
TradingView
Direct company coverage
Total liabilities & shareholders' equities of MiNK Therapeutics, Inc. – DUS:6Q40
This article provides financial data on total liabilities and shareholders' equities for MiNK Therapeutics, Inc. (DUS:6Q40) as listed on the Dusseldorf Stock Exchange. It highlights the availability of this specific financial metric from TradingView, which sources its data from I
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 19:10
- Source
- TradingView
Stock Titan
Direct company coverage
MiNK Therapeutics (INKT) investors reelect board members and ratify KPMG at 2026 meeting
MiNK Therapeutics, Inc. held its Annual Meeting of Stockholders on June 17, 2026, where investors reelected Garo Armen, Barbara Ryan, and John Holcomb as Class II directors for three-year terms. Additionally, stockholders ratified the appointment of KPMG LLP as the independent re
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 14:10
- Source
- Stock Titan
Quartr
Direct company coverage
Mink Therapeutics (INKT) AGM 2026 Summary
The Mink Therapeutics (INKT) Annual General Meeting (AGM) 2026 summary details the formal proceedings, including the appointment of an Inspector of Elections and the establishment of a quorum. Key voting outcomes included the approval of three Class II directors for three-year te
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 22 Jun 2026 21:11
- Source
- Quartr
Stock Traders Daily
Direct company coverage
Avoiding Lag: Real-Time Signals in (INKT) Movement
The article analyzes Mink Therapeutics Inc. (NASDAQ: INKT), highlighting mixed sentiment leading to choppy conditions. It reveals an exceptional 295.0:1 risk-reward setup, targeting a 93.5% gain, and outlines specific trading strategies (Position, Momentum Breakout, Risk Hedging)
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 21 Jun 2026 21:20
- Source
- Stock Traders Daily
TradingView
Direct company coverage
Inventory turnover of MiNK Therapeutics, Inc. – DUS:6Q40
The article discusses the inventory turnover of MiNK Therapeutics, Inc. (DUS: 6Q40) on the Dusseldorf Stock Exchange. It provides general financial information about the company's stock activity, noting that the market is currently closed with no trades. The content primarily foc
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Jun 2026 16:10
- Source
- TradingView
TradingView
Direct company coverage
Book value per share of MiNK Therapeutics, Inc. – DUS:6Q40
This article provides financial information for MiNK Therapeutics, Inc. (DUS:6Q40), specifically focusing on its book value per share. The content is presented within the TradingView platform, noting that the market is currently closed for this stock.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 15:11
- Source
- TradingView
TradingView
Direct company coverage
MiNK Therapeutics, Inc. Cash Flow – DUS:6Q40
This article provides key cash flow figures for MiNK Therapeutics, Inc. (DUS:6Q40). It highlights that the free cash flow for Q1 2026 was -1.50M EUR, and for the full year 2025, operating cash flow and free cash flow were both -5.04M EUR. The article also presents a historical br
- Tone
- Negative 39/100
- Event
- Balance sheet
- Published
- 19 Jun 2026 09:39
- Source
- TradingView
TradingKey
Direct company coverage
Mink Therapeutics Inc (INKT) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Mink Therapeutics Inc (INKT), focusing on key metrics like P/E, P/B, P/S, and P/CF ratios. It highlights that relevant data for these valuation dimensions have not yet been disclosed by the company. The page also presents current sto
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 10:09
- Source
- TradingKey